<DOC>
	<DOCNO>NCT02960893</DOCNO>
	<brief_summary>The purpose study compare efficacy BHV-4157 versus placebo ataxia symptom subject spinocerebellar ataxia ( SCA ) .</brief_summary>
	<brief_title>Trial Adult Subjects With Spinocerebellar Ataxia</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Machado-Joseph Disease</mesh_term>
	<criteria>Subjects know suspected diagnosis follow specific hereditary ataxia : SCA1 , SCA2 , SCA3 ( A Maximum 12 patient enrol genotype FEB 1 2017 THIS CAP HAS BEEN MET FOR SCA3 ) , SCA6 , SCA7 , SCA8 SCA10 Ability ambulate 8 meter without assistance ( cane device allow ) Screening total SARA total score â‰¥8 Determined investigator medically stable baseline/randomization must physically able expect complete trial design Subjects must adequate hearing , vision , language skill perform SARA rating , 8 Meter Walk Test neuropsychiatric test interview specify protocol Any medical condition one hereditary ataxia specify inclusion criterion could predominantly explain contribute significantly subject ' symptom ataxia MMSE score &lt; 24 SARA total score &gt; 30 point screen Clinical history stroke Active liver disease history hepatic intolerance medication investigator 's judgment , medically significant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ataxia</keyword>
	<keyword>SCA</keyword>
	<keyword>Spinocerebellar Ataxia</keyword>
</DOC>